Literature DB >> 28849072

c‑Myc promotes cholangiocarcinoma cells to overcome contact inhibition via the mTOR pathway.

Guosong Luo1, Bin Li2, Chunyan Duan3, Ying Cheng3, Bin Xiao3, Fuli Yao3, Mei Wei4, Qinghua Tao5, Chunhong Feng1, Xianming Xia1, Hong Zhou3, Xiaofang Zhao2, Rongyang Dai2.   

Abstract

The loss of contact inhibition is a hallmark of a wide range of human cancer cells. Yet, the precise mechanism behind this process is not fully understood. c‑Myc plays a pivotal role in carcinogenesis, but its involvement in regulating contact inhibition has not been explored to date. Here, we report that c‑Myc plays an important role in abrogating contact inhibition in human cholangiocarcinoma (CCA) cells. Our data show that the protein level of c‑Myc obviously decreased in contact-inhibited normal biliary epithelial cells. However, CCA cells sustain high protein levels of c‑Myc and keep strong proliferation ability in confluent conditions. Importantly, the suppression of c‑Myc by inhibitor or siRNA induced G0/G1 phase cell cycle arrest in confluent CCA cells. We demonstrate that the inhibition of c‑Myc suppressed the activity of mammalian target of rapamycin (mTOR) in confluent CCA cells, and mTOR inhibition induced G0/G1 phase cell cycle arrest in confluent CCA cells. In confluent CCA cells, the activity of Merlin is downregulated, and Yes-associated protein (YAP) sustains high levels of activity. Furthermore, YAP inhibition not only induced G0/G1 phase cell cycle arrest, but also decreased c‑Myc expression in confluent CCA cells. These results indicate that Merlin/YAP/c‑Myc/mTOR signaling axis promotes human CCA cell proliferation by overriding contact inhibition. We propose that overriding c‑Myc‑mediated contact inhibition is implicated in the development of CCA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28849072     DOI: 10.3892/or.2017.5913

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Baicalin Induced Apoptosis of Human Cholangiocarcinoma Cell through Activating AMPK/mTORC1/p70S6K Signaling Pathway.

Authors:  M Jia; F Yang; Y Xu; Q Xu; Y Zeng; R Dai; Y Xiang
Journal:  Bull Exp Biol Med       Date:  2022-07-20       Impact factor: 0.737

2.  Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization.

Authors:  Ka-Won Kang; Seung-Jin Lee; Ji Hye Kim; Byung-Hyun Lee; Seok Jin Kim; Yong Park; Byung Soo Kim
Journal:  BMC Cancer       Date:  2020-07-02       Impact factor: 4.430

Review 3.  PCAT-1: A Novel Oncogenic Long Non-Coding RNA in Human Cancers.

Authors:  Tiefu Xiong; Jianfa Li; Fangfang Chen; Fangting Zhang
Journal:  Int J Biol Sci       Date:  2019-03-01       Impact factor: 6.580

4.  Construction of a model to predict the prognosis of patients with cholangiocarcinoma using alternative splicing events.

Authors:  Hua-Yu Wu; Yi Wei; Li-Min Liu; Zhong-Biao Chen; Qi-Ping Hu; Shang-Ling Pan
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

5.  Upregulation of miR‑132‑3p in cholangiocarcinoma tissues: A study based on RT‑qPCR, The Cancer Genome Atlas miRNA sequencing, Gene Expression Omnibus microarray data and bioinformatics analyses.

Authors:  Hua-Yu Wu; Shuang Xia; An-Gui Liu; Min-Da Wei; Zhong-Biao Chen; Yu-Xin Li; Yu He; Min-Jun Liao; Qi-Ping Hu; Shang-Ling Pan
Journal:  Mol Med Rep       Date:  2019-10-07       Impact factor: 2.952

6.  Identification of key genes and pathways associated with cholangiocarcinoma development based on weighted gene correlation network analysis.

Authors:  Jingwei Liu; Weixin Liu; Hao Li; Qiuping Deng; Meiqi Yang; Xuemei Li; Zeng Liang
Journal:  PeerJ       Date:  2019-10-31       Impact factor: 2.984

7.  Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells.

Authors:  Ting La; Song Chen; Tao Guo; Xiao Hong Zhao; Liu Teng; Dandan Li; Michael Carnell; Yuan Yuan Zhang; Yu Chen Feng; Nicole Cole; Alexandra C Brown; Didi Zhang; Qihan Dong; Jenny Y Wang; Huixia Cao; Tao Liu; Rick F Thorne; Feng-Min Shao; Xu Dong Zhang; Lei Jin
Journal:  Theranostics       Date:  2021-09-21       Impact factor: 11.556

8.  Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.

Authors:  Hera Saqub; Hannah Proetsch-Gugerbauer; Vladimir Bezrookove; Mehdi Nosrati; Edith M Vaquero; David de Semir; Ryan J Ice; Sean McAllister; Liliana Soroceanu; Mohammed Kashani-Sabet; Robert Osorio; Altaf A Dar
Journal:  Sci Rep       Date:  2020-10-28       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.